Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
Clinical trial NCT00393029 · COMPLETED
Trial details
- NCT number
- NCT00393029
- Sponsor
- National Cancer Institute (NCI)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2006-10-01
- Primary completion
- 2008-11-01
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.